QL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
QL01 ANTINEOPLASTIC AGENTS
QL01E PROTEIN KINASE INHIBITORS
QL01EJ Janus-associated kinase (JAK) inhibitors
QL01EJ01 ruxolitinib
Last updated: 2024-12-27
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway
Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway
Tel: +47 21 07 81 60
E-mail:
Copyright/Disclaimer
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway
Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway
Tel: +47 21 07 81 60
E-mail:
Copyright/Disclaimer